Skip to main content

ADA Technologies Wins $1.15M NIH Grant

NEW YORK (GenomeWeb News) – ADA Technologies has landed a $1.15 million grant from the National Institutes of Health to develop an analytical tool for analyzing carbohydrate-protein interactions in drug discovery and diagnostics research.

The company will use the three-year Phase 2 funding to develop a microarray platform for rapidly analyzing carbohydrate and protein interactions that serve as cancer biomarkers.

ADA said that there currently is no cost-effective tool for quickly screening for such interactions.

"Carbohydrates are potential targets for anti-cancer immunotherapy, since they are exposed at the surface of tumor cells, but hidden on normal cells. Many bacteria and other pathogens are also distinguished by carbohydrates, making them good targets for vaccines," said Xichun Zhou, a senior research scientist and principal investigator at ADA.

"Development of an inexpensive glycan analytical tool that has a high degree of accuracy could have major impact on drug discovery and the biopharmaceutical industry, as well as the diagnostic industry," Zhou added.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.